molgramostim
Protein / enzyme therapeutic
Evidence outlook · regulatory review
Autoimmune Pulmonary Alveolar Proteinosis: application under FDA review, decision date 2026-11-22
Molgramostim BLA PDUFA target action date (Priority Review, extended) (2026-11-22). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
IMPALA-2 (NCT04544293): People were randomized 1:1 to molgramostim or matching placebo with quadruple blinding, and the primary endpoint, change in lung gas transfer (DLCO), was measured by a standardized lung function test and met its significance test. The trial is of moderate size (164 people) for a rare disease.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
IMPALA-2 NCT04544293 · Autoimmune Pulmonary Alveolar Proteinosis People were randomized 1:1 to molgramostim or matching placebo with quadruple blinding, and the primary endpoint, change in lung gas transfer (DLCO), was measured by a standardized lung function test and met its significance test. The trial is of moderate size (164 people) for a rare disease. Registry: NCT04544293 | 3 | Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24 (From Baseline to Week 24) 2023-11-30 | Primary endpoint, change in hemoglobin-adjusted DLCO (% predicted) from baseline to week 24 (LS mean): molgramostim 9.8 (95% CI 7.3 to 12.3, n=81) vs placebo 3.8 (95% CI 1.4 to 6.3, n=83); difference 6.0 percentage points (95% CI 2.5 to 9.4), p=0.0007. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow molgramostim to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent